Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Encapsulated Benzoyl Peroxide · 1 trial · 1 indication
Facial microbiome sampling will be performed on-site by collecting follicular samples as well as utilizing facial swabs.
transepidermal water loss in g/m2/h
stratum corneum water content (wt%)
sebum production in µg/cm2
facial L\*a\*b\* values
| Arm | Type | Description |
|---|---|---|
| Study Drug | EXPERIMENTAL | Daily Encapsulated Benzoyl Peroxide (E-BPO) Cream, for 8 weeks (period 1). Subjects will then switch treatments to the vehicle cream for a period of 4 weeks (period 2), |
| Vehicle | PLACEBO_COMPARATOR | Daily Vehicle Cream, for 8 weeks (period 1). Subjects will then switch treatments to the study drug encapsulated E-BPO for a period of 4 weeks (period 2), |
| Name | Type | Description |
|---|---|---|
| Encapsulated Benzoyl Peroxide Cream | DRUG | Subjects will use a "pea-size" amount for each area of the face |
Inclusion Criteria: * Participants must sign an Institutional Review Board (IRB) approved written informed consent for this study. * Male and female 18 years of age and older. * Participants must have clinical diagnosis of moderate to severe rosacea. * Have a minimum total of 15 and a maximum of 70...
Encapsulated Benzoyl Peroxide is an investigational small molecule being developed for the treatment of papulopustular rosacea, a form of rosacea characterized by redness and pus-filled bumps. It is applied topically and is currently in Phase 1 clinical development.
Encapsulated Benzoyl Peroxide is being developed by Sol-Gel Technologies Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SLGL. The company is conducting clinical research on this topical treatment for papulopustular rosacea.
Encapsulated Benzoyl Peroxide is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under evaluation for papulopustular rosacea.
Encapsulated Benzoyl Peroxide has one completed clinical trial, NCT05675501, titled "Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties." This Phase 1 study enrolled 31 participants with papulopustular rosacea in the United States.
Encapsulated Benzoyl Peroxide is a formulation of benzoyl peroxide, a common acne treatment, designed for topical use in papulopustular rosacea. The encapsulation technology aims to deliver the active ingredient in a controlled manner, but it is not a different chemical entity.